Rhythm Pharmaceuticals (RYTM) Accounts Payables (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has 11 years of Accounts Payables data on file, last reported at $12.3 million in Q1 2026.

• On a quarterly basis, Accounts Payables rose 3.25% year-over-year to $12.3 million in Q1 2026; TTM through Mar 2026 was $12.3 million, a 3.25% increase from a year earlier, with the FY2025 full-year figure at $13.9 million, up 13.13% from the prior year.
• Accounts Payables for Q1 2026 stood at $12.3 million, down from $13.9 million in the prior quarter.
• Over the last five years, Accounts Payables for RYTM reached as high as $16.0 million in Q2 2025 and fell as low as $3.8 million in Q3 2023.
• Historically, Accounts Payables has averaged $9.1 million across 5 years, with a median of $8.4 million in 2023.
• Across the five-year window, Accounts Payables tumbled 45.81% in 2024 and soared 251.79% in 2025, its largest moves.
• Year by year, Accounts Payables stood at $4.8 million in 2022, then climbed by 1.83% to $4.9 million in 2023, then jumped by 152.36% to $12.3 million in 2024, then grew by 13.13% to $13.9 million in 2025, then dropped by 11.82% to $12.3 million in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $12.3 million in Q1 2026, $13.9 million in Q4 2025, and $13.6 million in Q3 2025.